SCHEMBL17834673

SCHEMBL17834673

CC(C)c1ccc(-c2ccc(-c3cnc(-c4ccc(C[C@H](NC(=O)c5ccc(C(C)(C)C)s5)C(=O)O)cc4)nc3)c(F)c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIFC1 Q9BW19 2/20 0.41
MME P08473 7/20 0.39
MCL1 Q07820 1/20 0.38
ALOX5AP P20292 3/20 0.37
FEN1 P39748 3/20 0.37
PDK1 Q15118 1/20 0.37
PDK2 Q15119 1/20 0.37
PDK3 Q15120 1/20 0.37
PDK4 Q16654 1/20 0.37
ECE1 P42892 2/20 0.36
ITGB1 P05556 4/20 0.35
ITGB3 P05106 3/20 0.35
ITGAV P06756 3/20 0.35
ITGA2B P08514 3/20 0.35
ITGA5 P08648 3/20 0.35
ITGB5 P18084 1/20 0.35
ITGA4 P13612 1/20 0.35
ITGB7 P26010 1/20 0.35
ACE P12821 1/20 0.35
ACE2 Q9BYF1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17834479 0.91 KIFC1 (0.48) KIFC1MMEMCL1ALOX5APFEN1
SCHEMBL17834497 0.91 KIFC1 (0.48) KIFC1MCL1ALOX5APFEN1ITGB1
SCHEMBL17834642 0.91 KIFC1 (0.43) KIFC1MMEMCL1ALOX5APFEN1
SCHEMBL22449158 0.90 MME (0.41) KIFC1MMEMCL1PDK1PDK2
SCHEMBL15036994 0.90 MME (0.41) KIFC1MMEMCL1PDK1PDK2
SCHEMBL17834623 0.90 KIFC1 (0.45) KIFC1MMEMCL1ALOX5APFEN1
SCHEMBL17834636 0.89 PYGL (0.35) KIFC1MMEALOX5APFEN1
SCHEMBL17825511 0.89 KIFC1 (0.41) KIFC1MMEMCL1ALOX5APFEN1
SCHEMBL17968845 0.89 KIFC1 (0.41) KIFC1MMEMCL1ALOX5APFEN1
SCHEMBL17834514 0.89 GPR132 (0.44) KIFC1MCL1ALOX5APFEN1PDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 EP disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 US disclosed
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-08-11 US disclosed
WO-2016094729-A1 GLP-1 RECEPTOR MODULATORS CELGENE INTERNATIONAL II SARL (CH) 2016-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R KIFC1 4738/4885MME 796/4885MCL1 2102/4885
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R KIFC1 4738/4885MME 796/4885MCL1 2102/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR KIFC1 4749/4885MME 919/4885MCL1 1664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.